comprehensive -WSS

comprehensive

author：knowledge 2025-09-29 11:20:23 - browse：399

Stock exchange — Drew Angerer/Getty Images

Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development.

The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： How one patient went off dialysis — and others can too

WSS

How generative AI ratchets up security threats for health systems

Investment in vaccine development is lagging, report finds

Researchers use wearables data and AI to predict preterm birth risk

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Humana’s losses in Medicare Advantage tank its stock

Inequities make cancer less preventable for women: report

explore

comprehensive

hotspot

23andMe had bad news about my health. I wish a person had delivered it

Address the ethical violations that led to 'Three Identical Strangers'

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How one patient went off dialysis — and others can too

In Memoriam: Notable people who died in 2023

Pancreatic cancer early detection could be helped by AI

Activists slam private health insurers over coverage restrictions

Ionis has late

Tori Bowie and the unacceptable rates of Black maternal death

Sudafed saga points to U.S. issues with evaluating older drugs

leisure time

How generative AI ratchets up security threats for health systems

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Paxlovid should be available without a positive Covid test

White House pharmacy plagued with problems, investigation finds

Kaiser Permanente unions announce official strike date

Shingles, which affected Dianne Feinstein, is on the rise

hotspot

knowledge

focus

hotspot